Drugs / JNJ-40346527
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03177460 | Jun 2017 → Jan 2024 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01572519 | Jul 2012 → Aug 2013 | Hodgkins lymphoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01054014 | Jan 2010 → Jan 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03557970 | Oct 2018 → Sep 2020 | acute myeloid leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01597739 | Jul 2012 → Apr 2013 | rheumatoid arthritis | Janssen Research & Development, LLC | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04121208 Comparator | Apr 2021 → Feb 2022 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | University of Oxford | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-40346527 | “OBJECTIVE: To assess the efficacy and safety of JNJ-40346527, a selective inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase” PMID 26233509 ↗ Aug 20154“A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma” NCT01572519 ↗ |
| Known as | edicotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03557970 ↗ |
| Action | Inhibit | “JNJ-40346527, an FMS Inhibitor” NCT01572519 ↗ |
| Route | Oral | “Volunteers will participate in 1 of 3 parts; Part 1: volunteers will receive a single oral (by mouth) dose of JNJ-40346527” NCT01054014 ↗ |
| Target | CSF1R | “The trial will investigate the effect of the drug JNJ-40346527 on CSF-1R (colony stimulating factor-1 receptor)” NCT04121208 ↗ |